FilingSEC EDGARS-1
Dare Bioscience Faces Delisting Risk Amid Recent Financing And Warrant Issuance
· SEC accepted
StageOngoing
Filing content
Dare Bioscience is undergoing a delisting hearing due to non-compliance with Nasdaq rules and recently issued common stock and warrants in a financing.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…